On this page
The short version: the ADHD medication shortage is still with us in 2026, but it’s better than it was. The squeeze that started in late 2022 has eased as regulators raised production limits and more generic makers came online, yet several stimulants still come and go on pharmacy shelves. If you take Adderall or a methylphenidate product, the occasional empty-handed trip to the pharmacy is still a real possibility.
In this update, we cover where things stand right now and what actually helps you maintain consistent treatment, as well as explain why the shortage has dragged on for so long.
Key takeaways
- The shortage that began in October 2022 has improved but isn’t over; the FDA drug shortage database and ASHP drug shortages list still show several stimulants in short supply.
- Generic immediate-release amphetamine salts are the hardest to find. Brand Vyvanse is generally available, while generic lisdexamfetamine is still spotty.
- The DEA set 2026 production quotas higher than proposed, lifting the lisdexamfetamine cap to about 51.3 million grams.
- If you can’t fill your script, you have options: call ahead to find stock, and ask your prescriber about a different form or a same-class alternative.
- Don’t ration doses or borrow someone else’s medication. Bring the problem to your prescriber instead.
Is there still an ADHD medication shortage in 2026?
Yes. As of June 2026, the ADHD medication shortage that began in October 2022 has improved but isn’t fully resolved. The FDA and ASHP still list several stimulants in short supply, including generic amphetamine salts and generic lisdexamfetamine, though availability is better than at the low point.
The shortage traces back to October 2022, when the FDA confirmed a nationwide Adderall shortage after Teva, the largest U.S. manufacturer of amphetamine mixed salts, hit manufacturing and packaging delays. What began with one company and one drug spread across manufacturers and dose strengths, and it has now run for more than three years. The picture in 2026 is patchy: some products and strengths fill without trouble, while others vanish for weeks at a time and reappear without warning. Because the status shifts week to week, the most reliable check is the live FDA and ASHP shortage lists, plus a quick call to your pharmacy before you need a refill. If your care has been disrupted, it’s worth revisiting your plan during a visit for ADHD care.
Which medications are affected
Most of the trouble sits in the stimulant class, and it splits cleanly by active ingredient. Here’s where the main ADHD medications stand as of June 2026.
| Medication | Status | Notes |
|---|---|---|
| Adderall, amphetamine mixed salts — IR and XR | In shortage | Generic immediate-release is hardest to find; certain strengths are worse than others |
| Vyvanse, lisdexamfetamine | Brand available; generic in shortage | Brand from Takeda is usually fillable; generic capsules are short from some makers |
| Ritalin / Concerta, methylphenidate — mainly ER | Intermittent shortage | Improved versus 2023–2024, but some extended-release strengths are still spotty |
Adderall shortage and generic amphetamine salts
The Adderall shortage remains the center of the story in 2026. Amphetamine mixed salts, the active ingredient in Adderall, are still listed in shortage in both immediate-release and extended-release forms. Generic immediate-release tablets are the toughest to track down, and availability swings by specific strength, so a dose your pharmacy stocked last month may be out this month even when other strengths sit on the shelf. Brand and generic supply don’t move in step either. The takeaway for anyone searching “Adderall shortage 2026”: expect improvement over the worst stretch, but plan for the occasional gap and refill early when you can.
Vyvanse shortage and generic lisdexamfetamine
When will the Vyvanse shortage end? There’s no confirmed date, but the trend is up. Brand Vyvanse from Takeda has generally stayed available; the generic Vyvanse shortage, generic lisdexamfetamine, is the main sticking point. The DEA raised the 2026 lisdexamfetamine quota to about 51.3 million grams, which should continue easing supply.
That brand-versus-generic split is what matters most here. If your pharmacy can’t get generic lisdexamfetamine, brand Vyvanse may still be in stock, and many insurers will approve the brand when the generic is unavailable. The generic, first launched in August 2023, now has many approved makers, but not all are producing at full tilt, so individual pharmacies still see gaps. Either way, we recommend a quick call to confirm stock before your refill date.
Ritalin and Concerta, methylphenidate shortage
Methylphenidate is the third major piece. Extended-release products, including generic Concerta and Ritalin LA, are still on the shortage list in 2026, with availability that comes and goes. The good news is that this class has improved more noticeably than the amphetamines since the 2023–2024 low point. Immediate-release methylphenidate is generally easier to fill than the long-acting versions. As with the others, the specific strength matters, and what’s out one week may be back the next.
Why the shortage has lasted so long
Why is there an Adderall shortage this far out? A few problems feed each other. The DEA caps how much stimulant can be made each year through production quotas, and demand has climbed as more adults are diagnosed. Manufacturers have also reported supply-chain, manufacturing, ingredient, and business problems.
Stimulants like amphetamine and methylphenidate are Schedule II controlled substances, so the DEA sets an annual “aggregate production quota,” a hard ceiling on how much active ingredient the whole country can make. When demand jumped, the ceiling didn’t move fast enough, and a shortfall opened up. A few things deepened it. One large generic maker, Ascent Pharmaceuticals, which produced a sizable share of generic amphetamine, was halted by the DEA over recordkeeping concerns around late 2022, pulling significant supply off the market.
Regulators have since pushed quotas up, including mid-year 2025 increases and the 2026 quotas, which the DEA set above what it first proposed. In its 2026 order, the DEA pointed to rising medical demand and to manufacturer-reported reasons that include supply-chain issues, manufacturing and quality problems, lack of active ingredients, and business decisions. Raising a quota helps, but it takes months for more raw material to turn into pills on a shelf, which is why relief has come gradually.
What to do if you can’t fill your prescription
If you can’t fill your ADHD prescription, start by calling pharmacies to find stock before the script is sent. If it’s out, ask about a different form or strength, and bring your prescriber in early on a backup plan. Don’t stretch or skip doses on your own — a short, proactive plan beats scrambling the day you run out.
Here’s a practical sequence that tends to work:
Alternatives to ask your provider about
No medication on this list is a swap to make yourself, and none of this is dosing advice; it’s a starting point for a conversation with the prescriber who knows you and your history. Still, it helps to walk in knowing the options. Alternatives generally fall into two buckets: a different medication in the same class, or a non-stimulant, which sits largely outside the shortage.
| If your medication is | Same-class options to ask about | Form / notes |
|---|---|---|
| An amphetamine, Adderall, Adderall XR | Dextroamphetamine, Dexedrine, Zenzedi, ProCentra, Dyanavel XR, Adzenys XR-ODT, Xelstrym, Mydayis | Includes a skin patch, Xelstrym, FDA-approved in 2022, and liquid or dissolvable forms that are sometimes easier to fill |
| Vyvanse, lisdexamfetamine | Brand Vyvanse when only the generic is short; otherwise an amphetamine option above | Switching brand for generic can be a workaround when the generic is unavailable |
| A methylphenidate, Ritalin, Concerta, Focalin | Dexmethylphenidate, Focalin, Focalin XR, Azstarys, Jornay PM, Daytrana, Quillivant XR, Cotempla XR-ODT | Patch, liquid, and chewable forms are sometimes in stock when tablets aren’t |
| Any stimulant, if you’d prefer non-controlled | Non-stimulants: atomoxetine, Strattera, viloxazine, Qelbree, guanfacine ER, Intuniv, clonidine ER, Kapvay | Not controlled substances; generally outside the shortage; taken daily and build up over several weeks |
The non-stimulant column is worth a closer look if shortages keep disrupting your care. Atomoxetine, Strattera, and viloxazine, Qelbree, work on a different brain chemical than stimulants do, while guanfacine, Intuniv, and clonidine, Kapvay, come at ADHD from another angle again. Because none are controlled substances, they aren’t tied to the DEA quotas, so their supply tends to be more reliable. They generally take a few weeks of daily use to reach full effect and they don’t suit everyone, but for some patients they turn a recurring pharmacy headache into a non-issue. Whether a stimulant alternative or a non-stimulant makes more sense depends on how you’ve responded to treatment before, which makes this a decision to work through with your prescriber.
How Zellig supports patients during shortages
Shortages are a moving target, and much of the stress comes from facing them alone at the pharmacy counter. In our practice, we treat shortage planning as part of routine ADHD care: we keep an eye on what’s actually fillable and stay ahead on backup options so we can adjust your plan before you run out.
Because Zellig provides care by secure video across Pennsylvania, you don’t have to wait weeks or drive to an office to sort out a gap in your medication. Through medication management, we can talk through same-class alternatives, non-stimulant options, prior authorizations, and ways to keep costs reasonable. If you’re new to us, you can get started with an evaluation, and current patients can always contact us when a refill hits a wall.
Frequently asked questions
When will the ADHD medication shortage end?
There’s no confirmed end date to the ADHD medication shortage. Supply has improved as the DEA raised production quotas and more generic makers ramped up, but the FDA and ASHP still list several stimulants in shortage as of June 2026. Most experts expect gradual improvement instead of a single moment when it’s declared over.
Why is there an Adderall shortage?
There’s an Adderall shortage for a stack of reasons. The DEA caps how much stimulant can be produced each year, and demand has risen as more adults are diagnosed. Manufacturers have also reported supply-chain, manufacturing, ingredient, and business problems. A major generic maker was halted in 2022, which pulled a large share of supply off the market.
Can I switch ADHD medications during the shortage?
Often yes, with your prescriber, you can switch ADHD medications during the shortage. A different medication in the same class, or a non-stimulant like atomoxetine or viloxazine, may be in stock when your usual one isn’t. Doses aren’t interchangeable one-for-one, so your prescriber needs to convert the dose for you, safely.
Is there still an Adderall shortage in 2026?
Yes, there’s still an Adderall shortage in 2026, athough it’s easing. Amphetamine mixed salts are still listed in shortage, and generic immediate-release versions are the hardest to find. Availability varies by strength and pharmacy, so calling ahead and refilling early are the most reliable ways to avoid a gap.
This article is for general education and isn’t medical advice, a diagnosis, or a substitute for care from your own clinician. Medication decisions, including starting, stopping, switching, or adjusting any ADHD treatment, should be made with your prescriber. Drug shortage statuses change frequently; check the FDA and ASHP shortage databases for the latest.
Riley Guinan, PA-C
Riley is a board-certified physician assistant. She earned her Master of Science in Physician Assistant Studies from Thomas Jefferson University. Her clinical background includes outpatient psychiatry and inpatient behavioral health, including care for patients with co-occurring substance use and medical conditions. At Zellig Psychiatry, she provides psychiatric evaluations and medication management for adolescents and adults.